Notice of AGM

RNS Number : 6431D

ValiRx PLC

31 March 2014

 

This is a correction of the announcement from 7:01 28 March 2014 GMT.  It corrects the date, time and location of the Annual General Meeting to 23 April 2014 at 10:00am at the offices of Pinsent Masons LLP, 30 Crown Place, London EC2A 4ES.  All other details in the announcement were correct.  The full text of the corrected announcement is set out below.

31 March 2014

ValiRx Plc

("ValiRx" or "the Company")

Posting of Annual Report and Accounts

&

Notice of Annual General Meeting

 ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that its Annual Report and Accounts for the year ended 31 December 2013 have been published, are available on its website www.valirx.com and will be posted to shareholders later today.

The Company also advises that the Notice of its Annual general Meeting ("AGM") is available on its website, www.valirx.com and is being posted to shareholders later today. The Company's AGM will be held on 23 April 2014 at 10.00am at the offices Pinsent Masons LLP, 30 Crown Place, London EC2A 4ES.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker)	Tel: [phone]
David Hart
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment

 

END

 

 

NOASDUFIFFLSEDD